Drugs / AD816
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05793684 | Apr → Nov 2023 | obstructive sleep apnea syndrome | Apnimed | Completed | Met primary |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AD816 | “Week 1: AD816 low dose; Week 2: AD816 high dose” NCT05793684 ↗ |